MCID: BLS001
MIFTS: 58

Blau Syndrome malady

Categories: Genetic diseases, Rare diseases, Neuronal diseases, Skin diseases

Aliases & Classifications for Blau Syndrome

About this section

Aliases & Descriptions for Blau Syndrome:

Name: Blau Syndrome 49 10 11 45 22 23 47 12 67
Arthrocutaneouveal Granulomatosis 10 45 23 67
Jabs Syndrome 10 45 67
Granulomatous Inflammatory Arthritis, Dermatitis, and Uveitis, Familial 45 23
Familial Juvenile Systemic Granulomatosis 23 67
Blaus 67 24
Acug 45 67
Familial Granulomatous Inflammatory Arthritis Dermatitis and Uveitis 67
Synovitis, Granulomatous, with Uveitis and Cranial Neuropathies 65
 
Synovitis Granulomatous with Uveitis and Cranial Neuropathies 45
Granulomatosis, Familial Juvenile Systemic 45
Granulomatosis, Familial, Blau Type 45
Familial Granulomatosis, Blau Type 23
Pediatric Granulomatous Arthritis 23
Familial Granulomatosis Blau Type 67
Sarcoidosis, Early-Onset 65
Early-Onset Sarcoidosis 23

Characteristics:

HPO:

61
blau syndrome:
Inheritance: autosomal dominant inheritance


Classifications:



External Ids:

OMIM49 186580
Disease Ontology10 DOID:0050678
NCIt42 C116794
MedGen34 C1861303
UMLS65 C1861303, C1836122

Summaries for Blau Syndrome

About this section
NIH Rare Diseases:45 Blau syndrome is a rare condition characterized mainly by skin rash, arthritis and uveitis. it has variable expressivity and usually affects preschool age children younger than four years of age. characteristic findings include synovial effusions (fluid in the joints due to inflammation) and cysts, anterior uveitis (swelling and irritation of the uvea) and focal posterior synechiae (adhesion of the iris to the cornea). permanent bending of the fingers and toes (camptodactyly) and other findings have also been reported. it is caused by mutations in the nod2 gene and is inherited in an autosomal dominant manner. blau syndrome and early-onset sarcoidosis have the same symptoms and genetic cause, but early-onset sarcoidosis is caused by de novo (new) mutations and occurs sporadically (in individuals with no history of the disorder in the family). last updated: 5/5/2011

MalaCards based summary: Blau Syndrome, also known as arthrocutaneouveal granulomatosis, is related to sarcoidosis, early-onset and artery disease, and has symptoms including arthralgia, joint swelling and limitation of joint mobility. An important gene associated with Blau Syndrome is NOD2 (Nucleotide Binding Oligomerization Domain Containing 2), and among its related pathways are Canonical NF-kappaB pathway and Cellular roles of Anthrax toxin. Affiliated tissues include skin, eye and heart, and related mouse phenotypes are skeleton and immune system.

Disease Ontology:10 An autosomal dominant disease characterized by familial granulomatous arthritis, uveitis and skin granulomas caused by NOD2/CARD15 mutations.

Genetics Home Reference:23 Blau syndrome is an inflammatory disorder that primarily affects the skin, joints, and eyes. Signs and symptoms begin in childhood, usually before age 4.

UniProtKB/Swiss-Prot:67 Blau syndrome: A rare autosomal dominant disorder characterized by early-onset granulomatous arthritis, uveitis and skin rash.

Wikipedia:68 In 1985 Edward Blau, a pediatrician in Marshfield Wisconsin, reported a family that over four... more...

Description from OMIM:49 186580

Related Diseases for Blau Syndrome

About this section

Diseases related to Blau Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 196)
idRelated DiseaseScoreTop Affiliating Genes
1sarcoidosis, early-onset30.5HLA-DQA1, IL1B, MEFV, MVK, NLRP3, NOD1
2artery disease30.2HLA-DQA1, TNF
3malaria29.6IL1B, NLRP3, TLR4, TNF
4asthma29.5HLA-DQA1, IL1B, NLRP3, TNF
5rheumatoid arthritis29.2HLA-DQA1, IL1B, NLRP3, TLR4, TNF
6cooper-jabs syndrome12.3
7craniolenticulosutural dysplasia11.8
8sarcoidosis 110.5
9pustulosis of palm and sole10.4NOD2, TNF
10gastroduodenal crohn's disease10.4NOD2, TNF
11polycythemia10.4IL1B, TNF
12stargardt macular degeneration absent or hypoplastic corpus callosum mental retardation and dysmorphic features10.4IL1B, TNF
13plantar nerve lesion10.4IL1B, TNF
14peyronie's disease10.4IL1B, TNF
15mammary paget's disease10.4IL1B, TNF
16hidradenitis10.4NOD2, TNF
17lujo hemorrhagic fever10.4IL1B, TNF
18capillary lymphangioma10.4NOD2, TNF
19chromosome 9p deletion syndrome10.4NOD2, TNF
20residual stage angle-closure glaucoma10.4IL1B, TNF
21testicular granulosa cell tumor10.4IL1B, TNF
22phenylketonuria10.4
23refractory plasma cell neoplasm10.4IL1B, TNF
24skin conditions10.3IL1B, TNF
25rin2 syndrome10.3NOD2, TLR4
26postsurgical hypothyroidism10.3IL1B, TNF
27acute leukemia of ambiguous lineage10.3NOD2, TNF
28chagas disease10.3TLR4, TNF
29benign focal amyotrophy10.3IL1B, TNF
30opportunistic bacterial infectious disease10.3IL1B, TNF
31dentin caries10.3IL1B, TNF
32meier-gorlin syndrome 310.3HLA-DQA1, NOD2
33cryoglobulinemia10.3NOD2, TNF
34anti-hla hyperimmunization10.3TLR4, TNF
35protein r deficiency10.3IL1B, TLR4
36secretory diarrhea10.3IL1B, TNF
37blau syndrome10.3HLA-DQA1, NOD2
38breast cancer10.3
39photokeratitis10.3IL1B, TLR4
40meige syndrome10.3IL1B, TNF
41pustulosis palmaris et plantaris10.3NOD2, TNF
42skin amelanotic melanoma10.3IL1B, TLR4
43drug-induced mental disorder10.3HLA-DQA1, TNF
44tracheal stenosis10.3IL1B, TNF
45alcoholic gastritis10.2IL1B, TLR4
46cryptosporidiosis10.2HLA-DQA1, TNF
47basilar artery occlusion10.2TLR4, TNF
48atherosclerosis10.2
49lymphoma10.2
50cerebritis10.2

Graphical network of the top 20 diseases related to Blau Syndrome:



Diseases related to blau syndrome

Symptoms for Blau Syndrome

About this section

Symptoms by clinical synopsis from OMIM:

186580

Clinical features from OMIM:

186580

HPO human phenotypes related to Blau Syndrome:

(show all 54)
id Description Frequency HPO Source Accession
1 arthralgia hallmark (90%) HP:0002829
2 joint swelling hallmark (90%) HP:0001386
3 limitation of joint mobility hallmark (90%) HP:0001376
4 arthritis hallmark (90%) HP:0001369
5 hypermelanotic macule hallmark (90%) HP:0001034
6 skin rash hallmark (90%) HP:0000988
7 camptodactyly of finger typical (50%) HP:0100490
8 abnormality of temperature regulation typical (50%) HP:0004370
9 dry skin typical (50%) HP:0000958
10 photophobia typical (50%) HP:0000613
11 cataract typical (50%) HP:0000518
12 glaucoma typical (50%) HP:0000501
13 skin ulcer occasional (7.5%) HP:0200042
14 retrobulbar optic neuritis occasional (7.5%) HP:0100654
15 facial palsy occasional (7.5%) HP:0010628
16 abnormality of the salivary glands occasional (7.5%) HP:0010286
17 renal neoplasm occasional (7.5%) HP:0009726
18 ichthyosis occasional (7.5%) HP:0008064
19 dilatation of the ascending aorta occasional (7.5%) HP:0005111
20 lymphadenopathy occasional (7.5%) HP:0002716
21 vasculitis occasional (7.5%) HP:0002633
22 respiratory insufficiency occasional (7.5%) HP:0002093
23 pulmonary hypertension occasional (7.5%) HP:0002092
24 morphological abnormality of the central nervous system occasional (7.5%) HP:0002011
25 subcutaneous hemorrhage occasional (7.5%) HP:0001933
26 anemia occasional (7.5%) HP:0001903
27 splenomegaly occasional (7.5%) HP:0001744
28 abnormality of the pericardium occasional (7.5%) HP:0001697
29 abnormality of the liver occasional (7.5%) HP:0001392
30 choroideremia occasional (7.5%) HP:0001139
31 hypertension occasional (7.5%) HP:0000822
32 optic atrophy occasional (7.5%) HP:0000648
33 visual impairment occasional (7.5%) HP:0000505
34 retinopathy occasional (7.5%) HP:0000488
35 xerostomia occasional (7.5%) HP:0000217
36 nephropathy occasional (7.5%) HP:0000112
37 renal insufficiency occasional (7.5%) HP:0000083
38 skin ulcer HP:0200042
39 synovitis HP:0100769
40 camptodactyly of finger HP:0100490
41 cystoid macular edema HP:0011505
42 nongranulomatous uveitis HP:0007813
43 intermittent generalized erythematous papular rash HP:0007432
44 flexion contracture of toe HP:0005830
45 joint swelling HP:0001386
46 arthritis HP:0001369
47 abnormality of the cranial nerves HP:0001291
48 iritis HP:0001101
49 eczema HP:0000964
50 abnormality of the ear HP:0000598
51 band keratopathy HP:0000585
52 uveitis HP:0000554
53 cataract HP:0000518
54 glaucoma HP:0000501

Drugs & Therapeutics for Blau Syndrome

About this section

Drugs for Blau Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 14)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
DaunorubicinapprovedPhase 225220830-81-330323
Synonyms:
(+)-Daunomycin
(1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside
(7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
(7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
(8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione
(8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro--6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione
11006-54-5
11048-29-6
1407-15-4
149541-57-1
20830-81-3
23942-76-9
27576-81-4
28020-80-6
AB00514669
AC1L1JCP
AC1Q29OI
AI3-52942
Acetyladriamycin
Anthracyline
Antibiotics From Streptomyces Coeruleorubidus
Antibiotics from Streptomyces coeruleorubidus
BPBio1_000389
BRD-K43389675-003-02-7
BRN 1445583
BSPBio_000353
C01907
CCRIS 914
CHEBI:41977
CHEMBL178
CID30323
Cerubidin
Cerubidine
D07776
DAUNORUBICIN HCL
DB00694
DM1
Daunamycin
Daunarubicinum
Dauno-Rubidomycine
DaunoXome
DaunoXome (TN)
Daunoblastin
Daunoblastine
Daunomycin
 
Daunomycin Hydrochloride
Daunomycin, Hydrochloride
Daunorrubicina
Daunorubicin
Daunorubicin (INN)
Daunorubicin (liposomal)
Daunorubicin Hcl
Daunorubicin Hydrochloride
Daunorubicin [INN:BAN]
Daunorubicin, Hydrochloride
Daunorubicina
Daunorubicine
Daunorubicinum
Daunorubicinum [INN-Latin]
Daunoxome
EINECS 244-069-7
FI 6339
FI6339
HMS2089H04
HMS2091K06
HSDB 5095
LMPK13050002
LS-187381
LS-997
Leukaemomycin C
MolPort-002-533-961
NCGC00024246-05
NCGC00024246-06
NCGC00025173-01
NCI-C04693
NChemBio.2007.10-comp14
NSC 83142
NSC-82151
Ondena
Prestwick3_000487
RCRA waste no. U059
RP 13057
Rcra Waste No. U059
Rp 13057 Hydrochloride
Rubidomycin
Rubidomycin Hydrochloride
Rubomycin
Rubomycin C
Tocris-1467
UNII-ZS7284E0ZP
VS-103
daunorubicin
nchembio723-comp2
2
Cytarabineapproved, investigationalPhase 21035147-94-46253
Synonyms:
(beta-D-Arabinofuranosyl)cytosine
(beta-D-arabinofuranosyl)cytosine
1-.beta.-D-arabinofuranosyl-cytosine
1-Arabinofuranosylcytosine
1-beta -D-Arabinofaranosylcytosine
1-beta -D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone
1-beta -D-Arabinofuranosylcytosine
1-beta-D-Arabinofaranosylcytosine
1-beta-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone
1-beta-D-Arabinofuranosyl-Cytosine
1-beta-D-Arabinofuranosylcytosine
1-beta-D-Arabinofuranosylcytosine, Cytosine Arabinoside
1-beta-D-Arabinosyl-Cytosine
1-beta-D-Arabinosylcytosine
147-94-4
1beta -Arabinofuranasylcytosine
1beta -D-Arabinofuranosylcytosine
1beta -D-Arabinosylcytosine
1beta-Arabinofuranasylcytosine
1beta-D-Arabinofuranosylcytosine
1beta-D-Arabinosylcytosine
2(1H)-Pyrimidinone, 4-amino-1- -D-arabinofuranosyl- [CAS]
2(1H)-Pyrimidinone, 4-amino-1- -D-arabinofuranosyl
30399_FLUKA
4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin
4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin [Czech]
4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidine
4-Amino-1-b-D-arabinofuranosyl-2-(1H)-pyrimidinone
4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon
4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon [Czech]
4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone
4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
4-amino-1-beta-D-arabinofuranosylpyrimidin-2(1H)-one
69-74-9 (hydrochloride)
AC-1075
AC1L1M4F
AC1Q52OJ
AI3-52329
AR3
Alexan
Ara-C
Ara-C, Cytosine Arabinoside, Cytosar-U, Cytarabine
Ara-Cytidine
AraC
Arabinocytidine
Arabinofuranosyl Cytidine
Arabinofuranosylcytosine
Arabinosyl Cytosine
Arabinosylcytosine
Arabitin
Aracytidine
Aracytin
Aracytine
Arafcyt
BIDD:GT0371
BIDD:PXR0139
BTB15125
Beta-cytosine arabinoside
C02961
C1768_SIGMA
C2035
C9H13N3O5
CCRIS 913
CHEBI:28680
CHEMBL803
CHX 3311
CID6253
CPD000449317
CYTARABINE (SEE ALSO CYTARABINE HYDROCHLORIDE 69-74-9)
Citarabina
Citarabina [INN-Spanish]
Cytarabin
Cytarabina
Cytarabine
Cytarabine (JP15/USP/INN)
 
Cytarabine [USAN:INN:BAN:JAN]
Cytarabine liposome injection
Cytarabinoside
Cytarabinum
Cytarabinum [INN-Latin]
Cytarbel
Cytonal
Cytosar
Cytosar-U
Cytosine 1-beta-D-arabinofuranoside
Cytosine arabinofuranoside
Cytosine arabinose
Cytosine arabinoside
Cytosine arabinoside (VAN)
Cytosine beta-D-arabinofuranoside
Cytosine beta-D-arabinofuranoside hydrochloride
Cytosine beta-D-arabinoside
Cytosine, beta -D-arabinoside
Cytosine, beta-D-arabinoside
Cytosine-1-beta-D-arabinofuranoside
Cytosine-1-beta-D-arabinofuranoside hydrochloride
Cytosine-beta -D-arabinofuranoside
Cytosine-beta -arabinoside
Cytosine-beta-D-arabinofuranoside
Cytosine-beta-arabinoside
Cytosinearabinoside
D00168
DB00987
DepoCyte
Depocyt
Depocyt (TN)
Depocyt (liposomal)
Depocyte
EINECS 205-705-9
Erpalfa
FT-0082880
HMS2051K19
HMS2090A18
HSDB 3049
Intrathecal (injected into the spinal fluid) DepoCyt
Intrathecal cytarabine (also known as ara-C)
Iretin
LS-860
Lopac0_000316
MLS000758310
MLS001066340
MolPort-001-792-509
NCGC00093356-03
NCGC00093356-04
NCGC00093356-05
NCI-C04728
NSC 287459
NSC287459
S1648_Selleck
SAM001247012
SMR000449317
SR-01000075773-3
Spongocytidine
TL8001048
Tarabine
U 19920A
U-19,920
U-19920
UNII-04079A1RDZ
Udicil
ZINC03795098
beta -D-arabinosylcytosine
beta -arabinosylcytosine
beta -cytosine arabinoside
beta-Ara C
beta-Ara c
beta-Arabinosylcytosine
beta-Cytosine arabinoside
beta-D-Arabinosylcytosine
cytarabine
cytarabine liposome injection
cytosine-β-D-arabinofuranoside
3
Mitoxantroneapproved, investigationalPhase 225765271-80-94212
Synonyms:
1,4-Bis(2-(2-hydroxyethylamino)ethyl)amino)-5,8-dihydroxyanthraquinone
1,4-DIHYDROXY-5,8-BIS({2-[(2-HYDROXYETHYL)AMINO]ETHYL}AMINO)-9,10-ANTHRACENEDIONE
1,4-DIHYDROXY-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)-9,10-anthracenedione
1,4-Dihydroxy-5,8-bis(2-((2-hydroxyethyl)amino)ethylamino)-9,10-anthracenedione
1,4-Dihydroxy-5,8-bis(5-hydroxy-3-azapentylamino)anthrachinon
1,4-Dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione
1,4-Dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedione
1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)anthra-9,10-quinone
1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)anthracene-9,10-dione
137635-96-2
2fum
5,8-Bis((2-((2-hydroxyethyl)amino)ethyl)amino)-1,4-dihydroxyanthraquinone
65271-80-9
70476-82-3
70476-82-3 (hydrochloride)
70711-41-0
70711-41-0 (acetate)
70945-62-9
9,10-Anthracenedione, 1,4-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino)- (9CI)
AB00053716
AC1L1HNY
AN-584/42007670
BIDD:PXR0181
BPBio1_000627
BRD-K21680192-300-05-2
BRD-K21680192-300-07-8
BRN 2795126
BSPBio_000569
BSPBio_003160
C11195
C22H28N4O6
CAS-70476-82-3
CCRIS 7604
CHEBI:50729
CHEMBL58
CID4212
D08224
DB01204
DHAD
DHAQ
DHAQ (*Diacetate salt*)
DHAQ HCl
Dihydroxyanthraquinone
DivK1c_000516
HMS2090D05
IDI1_000516
KBio1_000516
KBio2_002135
KBio2_004703
KBio2_007271
KBio3_002660
KBioGR_001531
KBioSS_002135
LS-20638
Liposome Encapsulated Mitoxantrone (LEM)
Lopac-M-6545
Lopac0_000779
MITOXANTRONE, 1,4-DIHYDROXY-5,8-BIS({2-[(2-HYDROXYETHYL)AMINO]ETHYL}AMINO)ANTHRA-9,10-QUINONE
MITOXANTRONE, Mitoxantrone Hydrochloride, Mitoxantrone dihydrochloride, MITOXANTHRONE HYDROCHLORIDE
MIX
MLS002703044
 
Misostol
Misostol (TN)
Mitox
Mitoxanthrone
Mitoxantron
Mitoxantrona
Mitoxantrona [INN-Spanish]
Mitoxantrone
Mitoxantrone (INN)
Mitoxantrone (free base)
Mitoxantrone 2HCl
Mitoxantrone HCl
Mitoxantrone Hydrochloride
Mitoxantrone [INN]
Mitoxantrone dihydrochloride
Mitoxantrone hydrochloride
Mitoxantronum
Mitoxantronum [INN-Latin]
Mitozantrone
Mitozantrone hydrochloride
MolPort-003-849-239
NCGC00015693-01
NCGC00015693-02
NCGC00015693-04
NCGC00162251-01
NCI60_002276
NCI60_002535
NChemBio.2007.10-comp17
NINDS_000516
NSC 279836
NSC-279836
NSC-287836
NSC-299195
NSC-301739
NSC-301739D
NSC279836
NSC299195
NSC301739
Neuro_000153
Novantron
Novantrone
Novantrone(R) (mitoxantrone for injection concentrate)
Prestwick0_000385
Prestwick1_000385
Prestwick2_000385
Prestwick3_000385
S2485_Selleck
SMP2_000179
SMR001549953
SPBio_000756
SPBio_002490
SR-01000076001
SR-01000076001-7
STK631833
Spectrum2_000908
Spectrum3_001590
Spectrum4_000866
Spectrum5_001205
Spectrum_001655
UNII-BZ114NVM5P
VU0244399-2
mitoxantrone
4Topoisomerase InhibitorsPhase 24081
5Immunologic FactorsPhase 218483
6Immunosuppressive AgentsPhase 210422
7Peripheral Nervous System AgentsPhase 218510
8Antiviral AgentsPhase 28071
9Antibiotics, AntitubercularPhase 25971
10Anti-Bacterial AgentsPhase 29140
11Anti-Infective AgentsPhase 217220
12AntimetabolitesPhase 29454
13Antimetabolites, AntineoplasticPhase 25770
14AnalgesicsPhase 29358

Interventional clinical trials:

idNameStatusNCT IDPhase
1Trial of Intensive Chemotherapy With or Without Volasertib in Patients With Newly Diagnosed High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)RecruitingNCT02198482Phase 2

Search NIH Clinical Center for Blau Syndrome

Genetic Tests for Blau Syndrome

About this section

Genetic tests related to Blau Syndrome:

id Genetic test Affiliating Genes
1 Blau Syndrome22 NOD2

Anatomical Context for Blau Syndrome

About this section

MalaCards organs/tissues related to Blau Syndrome:

33
Skin, Eye, Heart, Myeloid, Liver, Salivary gland, Kidney

Animal Models for Blau Syndrome or affiliated genes

About this section

MGI Mouse Phenotypes related to Blau Syndrome:

38
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053907.7IL1B, MEFV, NLRP3, NOD2, TLR4, TNF
2MP:00053877.0HLA-DQA1, IL1B, MEFV, NLRP3, NOD1, NOD2
3MP:00053976.9HLA-DQA1, IL1B, MEFV, NLRP3, NOD1, NOD2

Publications for Blau Syndrome

About this section

Articles related to Blau Syndrome:

(show top 50)    (show all 74)
idTitleAuthorsYear
1
The role of receptor for advanced glycation end products in airway inflammation in CF and CF related diabetes. (25754382)
2015
2
Variant of dermatofibrosarcoma protuberans: bednar tumor. (25657441)
2015
3
Formulation design for topical drug and nanoparticle treatment of skin disease. (25690087)
2015
4
Multiple endocrine disorders associated with adrenomyeloneuropathy and a novel mutation of the ABCD1 gene. (24685009)
2014
5
Four microRNAs promote prostate cell proliferation with regulation of PTEN and its downstream signals in vitro. (24098737)
2013
6
Posttraumatic intramedullary osteochondroma: report of a case. (23354526)
2013
7
Investigation of antimuscarinic receptor autoantibodies in patients with acquired idiopathic generalized anhidrosis. (24334576)
2013
8
Gankyrin activates IL-8 to promote hepatic metastasis of colorectal cancer. (23576566)
2013
9
Low coverage and predictors of vaccination uptake against tick-borne encephalitis in Slovenia. (21398380)
2012
10
Utility of peripheral blood flow cytometry in differentiating low grade versus high grade myelodysplastic syndromes (MDS) and in the evaluation of cytopenias. (22558477)
2012
11
Association between HRAS rs12628 and rs112587690 polymorphisms with the risk of melanoma in the North American population. (22618666)
2012
12
ER stress-mediated autophagy promotes Myc-dependent transformation and tumor growth. (23143306)
2012
13
A case of severe gastroparesis: indigestion and weight loss after catheter ablation of atrial fibrillation. (20883511)
2012
14
Physical activity attenuates the influence of FTO variants on obesity risk: a meta-analysis of 218,166 adults and 19,268 children. (22069379)
2011
15
Oncogenic B-RAF(V600E) promotes anchorage-independent survival of human melanocytes. (20445557)
2010
16
Progress and compliance in alcohol abuse treatment. (20031241)
2010
17
Immunohistochemical analysis of hMLH1 and hMSH2 proteins in serous ovarian tumours. (20072951)
2009
18
Role of prostaglandins and specific place in therapy of bimatoprost in the treatment of elevated intraocular pressure and ocular hypertension: A closer look at the agonist properties of bimatoprost and the prostamides. (20054414)
2009
19
Clinical relevance of Mycobacterium chelonae-abscessus group isolation in 95 patients. (19732795)
2009
20
Cerebral transplantation of encapsulated mesenchymal stem cells improves cellular pathology after experimental traumatic brain injury. (19638295)
2009
21
Processing mutations disrupt interactions between the nucleotide binding and transmembrane domains of P-glycoprotein and the cystic fibrosis transmembrane conductance regulator (CFTR). (18708637)
2008
22
Self-protection of individual CD4+ T cells against R5 HIV-1 infection by the synthesis of anti-viral CCR5 ligands. (18941536)
2008
23
Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II. (18448542)
2008
24
Images in emergency medicine. Superior vena cava syndrome. (17963979)
2007
25
Sonographic measurement of renal pelvis wall thickness as diagnostic criterion for acute pyelonephritis in adults. (18074313)
2007
26
The HNF-1alpha-SNARE connection. (17919177)
2007
27
Development and characterization of lipidic cochleate containing recombinant factor VIII. (17936245)
2007
28
Significant decrease in tropoelastin gene expression in fibroblasts from a Japanese Costello syndrome patient with impaired elastogenesis and enhanced proliferation. (16829682)
2006
29
Enzastaurin (LY317615), a protein kinase Cbeta inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell lines. (16891464)
2006
30
Analysis of PPAR alpha function in human kidney cell line using siRNA. (17150915)
2006
31
Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling. (16449486)
2006
32
Lifetime gain related to cost of repair of ruptured abdominal aortic aneurysm in octogenarians. (14760600)
2004
33
Atypical recognition consensus of CIN85/SETA/Ruk SH3 domains revealed by target-assisted iterative screening. (12829691)
2003
34
Evaluation of methods to solubilize and analyze cell-associated ectoenzymes. (12223287)
2002
35
AlphaMbeta2 (CD11b/CD18, Mac-1) integrin activation by a unique monoclonal antibody to alphaM I domain that is divalent cation-sensitive. (11073102)
2000
36
UCN-01 (7-hydroxystaurosporine) enhances 5-fluorouracil cytotoxicity through down-regulation of thymidylate synthetase messenger RNA. (11092986)
2000
37
Antibody response to the chlamydial heat-shock protein 60 in an experimental model of chronic pelvic inflammatory disease in monkeys (Macaca nemestrina). (10438366)
1999
38
Endothelin-1 infusion inhibits plasma insulin responsiveness in normal men. (9746115)
1998
39
Phospholipid hydroperoxide glutathione peroxidase activity of human glutathione transferases. (9576856)
1998
40
Haplotypic association of two new HLA class I alleles: Cw*15052 and B*0706: evolutionary relationships of HLA-Cw*15 alleles. (8773323)
1996
41
Combined choriocarcinoma, hepatoid adenocarcinoma, small cell carcinoma and tubular adenocarcinoma in the oesophagus. (8548132)
1995
42
N-acetylgalactosamine glycosylation of MUC1 tandem repeat peptides by pancreatic tumor cell extracts. (8033093)
1994
43
Role of differentiation induction in action of purine antimetabolites. (8032345)
1994
44
Anticardiolipin antibodies in rheumatoid arthritis: their relation to rheumatoid nodules and cutaneous vascular manifestations. (8043421)
1994
45
Inhibitory effect of interleukin-4 on the proliferation of acute myeloid leukemia cells with myelo-monocytic differentiation (AML-M4/M5); the role of interleukin-6. (8464242)
1993
46
Coordinate regulation of triacylglycerol synthesis and glucose transport by acylation-stimulating protein. (8492712)
1993
47
Atrial natriuretic factor: a protective role after acute renal ischaemia? A room for it in kidney transplantation? (2146848)
1990
48
Pontoneocerebellar hypoplasia: report of a case in a newborn and review of the literature. (2407401)
1990
49
Carotid artery disease and central retinal artery occlusion. (436273)
1979
50

Variations for Blau Syndrome

About this section

UniProtKB/Swiss-Prot genetic disease variations for Blau Syndrome:

67
id Symbol AA change Variation ID SNP ID
1NOD2p.Arg334GlnVAR_012676rs104895461
2NOD2p.Arg334TrpVAR_012677rs104895462
3NOD2p.Leu469PheVAR_012685rs104895460
4NOD2p.Glu383LysVAR_023823rs104895477
5NOD2p.Thr605AsnVAR_065228
6NOD2p.Pro507SerVAR_073180

Clinvar genetic disease variations for Blau Syndrome:

5
id Gene Variation Type Significance SNP ID Assembly Location
1NOD2NM_022162.2(NOD2): c.1001G> A (p.Arg334Gln)single nucleotide variantPathogenicrs104895461GRCh37Chr 16, 50744823: 50744823
2NOD2NM_022162.2(NOD2): c.1405C> T (p.Leu469Phe)single nucleotide variantPathogenicrs104895460GRCh37Chr 16, 50745227: 50745227
3NOD2NM_022162.2(NOD2): c.1000C> T (p.Arg334Trp)single nucleotide variantPathogenicrs104895462GRCh37Chr 16, 50744822: 50744822
4NOD2NM_022162.2(NOD2): c.1147G> A (p.Glu383Lys)single nucleotide variantPathogenicrs104895477GRCh37Chr 16, 50744969: 50744969

Expression for genes affiliated with Blau Syndrome

About this section
Search GEO for disease gene expression data for Blau Syndrome.

Pathways for genes affiliated with Blau Syndrome

About this section

Pathways related to Blau Syndrome according to GeneCards Suite gene sharing:

(show all 27)
idSuper pathwaysScoreTop Affiliating Genes
19.8NOD2, TNF
29.7IL1B, TNF
39.7IL1B, TNF
49.7IL1B, TNF
59.7IL1B, TNF
69.4IL1B, NOD2, TNF
79.2IL1B, NLRP3, TNF
8
Show member pathways
9.2IL1B, NOD1, NOD2
9
Show member pathways
9.2IL1B, TLR4, TNF
109.2IL1B, TLR4, TNF
11
Show member pathways
9.2IL1B, TLR4, TNF
12
Show member pathways
9.2IL1B, TLR4, TNF
139.2IL1B, TLR4, TNF
149.2IL1B, TLR4, TNF
159.2IL1B, TLR4, TNF
169.2IL1B, TLR4, TNF
179.2IL1B, TLR4, TNF
189.2IL1B, TLR4, TNF
198.8HLA-DQA1, IL1B, TLR4, TNF
20
Show member pathways
8.8HLA-DQA1, IL1B, TLR4, TNF
218.5HLA-DQA1, IL1B, NOD2, TLR4, TNF
22
Show member pathways
8.5HLA-DQA1, IL1B, NOD2, TLR4, TNF
23
Show member pathways
8.4HLA-DQA1, IL1B, NLRP3, TLR4, TNF
248.2IL1B, NLRP3, NOD1, TLR4, TNF
25
Show member pathways
7.9IL1B, NLRP3, NOD1, NOD2, TLR4, TNF
26
Show member pathways
7.8IL1B, MEFV, NLRP3, NOD1, NOD2, TNF
27
Show member pathways
6.9HLA-DQA1, IL1B, MEFV, NLRP3, NOD1, NOD2

GO Terms for genes affiliated with Blau Syndrome

About this section

Biological processes related to Blau Syndrome according to GeneCards Suite gene sharing:

(show top 50)    (show all 52)
idNameGO IDScoreTop Affiliating Genes
1positive regulation of calcidiol 1-monooxygenase activityGO:006055910.4IL1B, TNF
2positive regulation of membrane protein ectodomain proteolysisGO:005104410.4IL1B, TNF
3sequestering of triglycerideGO:003073010.4IL1B, TNF
4regulation of establishment of endothelial barrierGO:190314010.4IL1B, TNF
5positive regulation of chemokine biosynthetic processGO:004508010.4IL1B, TNF
6cellular response to muramyl dipeptideGO:007122510.4NOD1, NOD2
7detection of bacteriumGO:001604510.3NOD1, NOD2
8positive regulation of nitric oxide biosynthetic processGO:004542910.3IL1B, TNF
9positive regulation of fever generationGO:003162210.3IL1B, TNF
10negative regulation of lipid catabolic processGO:005099510.3IL1B, TNF
11negative regulation of extrinsic apoptotic signaling pathway in absence of ligandGO:200124010.3IL1B, TNF
12positive regulation of NIK/NF-kappaB signalingGO:190122410.3NOD1, TNF
13positive regulation of interleukin-8 biosynthetic processGO:004541610.3TLR4, TNF
14positive regulation of chemokine productionGO:003272210.3TLR4, TNF
15interleukin-1 beta productionGO:003261110.3IL1B, NLRP3
16positive regulation of nitric-oxide synthase biosynthetic processGO:005177010.3NOD2, TLR4
17positive regulation of interleukin-1 beta secretionGO:005071810.3NLRP3, NOD2
18regulation of I-kappaB kinase/NF-kappaB signalingGO:004312210.3IL1B, TNF
19regulation of inflammatory responseGO:005072710.2NOD2, TLR4
20positive regulation of phagocytosisGO:005076610.1IL1B, TNF
21toll-like receptor 10 signaling pathwayGO:003416610.1NOD1, NOD2
22negative regulation of interleukin-6 productionGO:003271510.1TLR4, TNF
23JNK cascadeGO:000725410.0NOD1, TNF
24lipopolysaccharide-mediated signaling pathwayGO:00316639.9IL1B, TLR4
25positive regulation of NF-kappaB import into nucleusGO:00423469.8IL1B, TLR4, TNF
26positive regulation of JUN kinase activityGO:00435079.8IL1B, TNF
27positive regulation of interleukin-8 productionGO:00327579.8IL1B, NOD2, TLR4
28positive regulation of cysteine-type endopeptidase activity involved in apoptotic processGO:00432809.7NLRP3, NOD1, TNF
29positive regulation of tumor necrosis factor productionGO:00327609.7NOD1, NOD2, TLR4
30positive regulation of interferon-gamma productionGO:00327299.7IL1B, TLR4, TNF
31nucleotide-binding domain, leucine rich repeat containing receptor signaling pathwayGO:00358729.7NLRP3, NOD1, NOD2
32toll-like receptor 4 signaling pathwayGO:00341429.6NOD1, NOD2, TLR4
33positive regulation of ERK1 and ERK2 cascadeGO:00703749.6IL1B, NOD1, NOD2
34protein oligomerizationGO:00512599.6NLRP3, NOD1, NOD2
35positive regulation of stress-activated MAPK cascadeGO:00328749.6IL1B, NOD1, TLR4
36toll-like receptor TLR1:TLR2 signaling pathwayGO:00381239.5NOD1, NOD2, TLR4
37toll-like receptor signaling pathwayGO:00022249.5NOD1, NOD2, TLR4
38positive regulation of interleukin-6 productionGO:00327559.5IL1B, TLR4, TNF
39immune responseGO:00069559.3IL1B, TLR4, TNF
40cellular response to lipopolysaccharideGO:00712229.3IL1B, TLR4, TNF
41defense responseGO:00069529.2NLRP3, NOD1, NOD2, TNF
42positive regulation of JNK cascadeGO:00463309.1IL1B, NOD1, NOD2, TLR4
43TRIF-dependent toll-like receptor signaling pathwayGO:00356669.1NOD1, NOD2, TLR4
44inflammatory responseGO:00069548.9IL1B, NLRP3, NOD1, TNF
45apoptotic processGO:00069158.8IL1B, NLRP3, NOD1, TLR4
46MyD88-independent toll-like receptor signaling pathwayGO:00027568.8NOD1, NOD2, TLR4
47activation of MAPK activityGO:00001878.8IL1B, NOD1, NOD2, TLR4, TNF
48defense response to bacteriumGO:00427428.8NOD1, NOD2, TLR4, TNF
49positive regulation of transcription from RNA polymerase II promoterGO:00459448.7IL1B, NOD2, TLR4, TNF
50positive regulation of NF-kappaB transcription factor activityGO:00510928.7IL1B, NLRP3, NOD1, NOD2, TNF

Sources for Blau Syndrome

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet